摘要:
The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
摘要:
Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
摘要:
The present invention provides novel methods for targeting an antigen to a dendritic cell using an antibody linked to the antigen. The present invention further provides methods of inducing or enhancing an immune response and methods of immunization using an antibody linked to the antigen.
摘要:
The present invention provides novel methods for targeting an antigen to a dendritic cell using an antibody linked to the antigen. The present invention further provides methods of inducing or enhancing an immune response and methods of immunization using an antibody linked to the antigen.
摘要:
The present invention provides human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
摘要:
Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
摘要:
The present invention provides human sequence antibodies against CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
摘要:
Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
摘要:
Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
摘要:
The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.